Medpace ($MEDP) Overstated Q4 2025 Booking Outlook and Cancellation Trends Case

Investors can submit applications for the lead plaintiff role.

S.D. Ohio

Court

1:26-cv-00346

Case number

04/06/2025

Class period Start

02/09/2026

Class period End

06/05/2026

Lead Plaintiff motion deadline

$MEDP investors filed a claim against Medpace for allegedly overstating how achievable its fourth-quarter 2025 book-to-bill target was while downplaying cancellation problems.
After Medpace reported a fourth-quarter 2025 book-to-bill ratio of 1.04 instead of its 1.15 target and said fourth-quarter cancellations had risen again, $MEDP fell 15.9% on February 10, 2026.
$MEDP investors can join this case to be notified about potential recovery.
Case Details:

Between April 22, 2025 and February 9, 2026, Medpace told investors it could return to a 1.15 book-to-bill ratio in the second half of 2025. Executives emphasized stable to improving funding, “well behaved” cancellations, strong award activity, and growth that was broad-based rather than tied to only a few studies.

However, during this period, investors allege Medpace was facing cancellation trends that made that outlook too optimistic. Medpace allegedly failed to disclose the backlog cancellations were high enough to threaten its fourth-quarter 2025 book-to-bill target. The cancellations, including in metabolic studies, were affecting bookings more than investors were told, and its pre-backlog and growth mix were less broad-based and more concentrated than the company suggested.

Then, on February 9, 2026, the company revealed a fourth-quarter 2025 book-to-bill ratio of 1.04, below guidance. $MEDP fell 15.9%, closing at $446.05. 

Additional revelations followed on February 10, 2026, including management’s statement that fourth-quarter backlog cancellations were elevated again and had reached their highest level in over a year. 

By February 10, 2026, shares had dropped to $446.05, representing a total decline of 15.9% over the correction period.

Based on these events, $MEDP investors filed a claim against Medpace, alleging the company:
It overstated how achievable a 1.15 book-to-bill ratio was for late 2025.
It downplayed cancellation problems and told investors those issues were under control.
It gave investors an overly positive picture of how broad and durable its booking and backlog trends were.
Investors argue Medpace misled the market about whether cancellations and booking trends could support its late-2025 outlook, causing losses when the truth emerged.

Case Type

US Securities Class Action

Case Status

Lead Plaintiff Submission

Alleged Offence

Misleading Statements,

Fraud,

Failure to Disclose,

Omissions

Suspected Party

Directors,

Management

Security Type

Stocks

Trade Direction

Long

Shock Event Date

02/09/2026

Filing date

04/06/2026

Lead Plaintiff Deadline

06/05/2026

Trusted by industry leaders

Endorsed by top professionals who trust our innovative solutions to drive impactful results.